Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Mudan He
China proposes biotech export restrictions
Photo: Cheng Xin/Getty Images The proposed rules prohibit outbound transfers of biotechnology platform ownership but expressly exempt ownership-retaining product licenses. Multinational corporations should structure transactions as product-specific licenses rather than platform or entity acquisitions to preserve deal viability.
China Proposes Biotech Export Restrictions: Implications for Licensees and Acquirers
The proposed rules prohibit outbound transfers of biotechnology platform ownership but expressly exempt ownership-retaining product licenses. Multinational corporations should structure transactions as product-specific licenses rather than platform or entity acquisitions to preserve deal viability. Proprietary technologies for discovering undisclosed novel targets lack single-product exemptions and face strict export restrictions.
China Proposes Biotech Export Restrictions: Implications for Licensees and Acquirers
LawFlash The proposed rules prohibit outbound transfers of biotechnology platform ownership but expressly exempt ownership-retaining product licenses. Multinational corporations should structure transactions as product-specific licenses rather than platform or entity acquisitions to preserve deal viability. Proprietary technologies for discovering undisclosed novel targets lack single-product exemptions and face strict export restrictions.
China Establishes New Individual Income Tax Rules for Offshore Trusts
China’s new rules generally treat a resident individual’s transfer of property into an offshore trust as a deemed disposition, imposing 20% individual income tax on any resulting gain rather than on the gross value of the transferred property. The era of relying on structural opacity for offshore tax planning has officially ended in China.
China Establishes New Individual Income Tax Rules for Offshore Trusts
China’s new rules generally treat a resident individual’s transfer of property into an offshore trust as a deemed disposition, imposing 20% individual income tax on any resulting gain rather than on the gross value of the transferred property. The era of relying on structural opacity for offshore tax planning has officially ended in China.
Regulation on Outbound Investment: Why Chinese Counterparty Compliance Is Now a Deal Risk
On June 1, 2026, China’s State Council promulgated the Regulation on Outbound Investment (《国务院关于对外投资的规定》), effective July 1. The Regulation provides the clearest legal basis yet for Chinese authorities to review and potentially prohibit cross-border transactions that could result in the transfer of critical technology, data, or strategic assets beyond Chinese jurisdiction, selecting three categories of activity that will now be expressly regulated.
Regulation on Outbound Investment: Why Chinese Counterparty Compliance Is Now a Deal Risk
On June 1, 2026, China’s State Council promulgated the Regulation on Outbound Investment (《国务院关于对外投资的规定》), effective July 1. The Regulation provides the clearest legal basis yet for Chinese authorities to review and potentially prohibit cross-border transactions that could result in the transfer of critical technology, data, or strategic assets beyond Chinese jurisdiction, selecting three categories of activity that will now be expressly regulated.
Strategic Compliance: Navigating HGR and Data Risks in China Life Sciences Transactions
For multinational companies and biotech companies engaging in “in-licensing” transactions with Chinese partners, the transfer of biological samples and clinical trial data is more than just a technical necessity, it is the deal’s most regulated bottleneck. It is important to understand China’s oversight on Human Genetic Resources and Personal Information, which creates significant compliance burdens that directly impact clinical and commercial timelines for foreign licensees.
Strategic Compliance: Navigating HGR and Data Risks in China Life Sciences Transactions
For multinational companies and biotech companies engaging in “in-licensing” transactions with Chinese partners, the transfer of biological samples and clinical trial data is more than just a technical necessity, it is the deal’s most regulated bottleneck. It is important to understand China’s oversight on Human Genetic Resources and Personal Information, which creates significant compliance burdens that directly impact clinical and commercial timelines for foreign licensees.
China’s Order 818: A New Commercialization Pathway Reshaping Cross-Border CGT Licensing and Investment
China now allows the commercialization of certain advanced therapies without requiring traditional drug registration through the National Medical Products Administration (NMPA).
The Manus Decision: China’s First AI Security Review Block and Implications for Cross-Border AI Investment
In April 2026, China’s National Development and Reform Commission (NDRC) blocked the acquisition of Manus, a Chinese-founded AI agent startup, by a major US technology company. This was the first publicly confirmed use of China’s foreign investment security review mechanism to unwind a cross-border AI transaction. The decision has significant implications for US venture capital funds, strategic acquirers, and institutional allocators with exposure to China-origin technology companies.
The Manus Decision: China’s First AI Security Review Block and Implications for Cross-Border AI Investment
In April 2026, China’s National Development and Reform Commission (NDRC) blocked the acquisition of Manus, a Chinese-founded AI agent startup, by a major US technology company. This was the first publicly confirmed use of China’s foreign investment security review mechanism to unwind a cross-border AI transaction. The decision has significant implications for US venture capital funds, strategic acquirers, and institutional allocators with exposure to China-origin technology companies.
China’s Order 818: A New Commercialization Pathway Reshaping Cross-Border CGT Licensing and Investment
China now allows the commercialization of certain advanced therapies without requiring traditional drug registration through the National Medical Products Administration (NMPA).
A Strategic Playbook for Chinese Biotech Cross-Border Deals: Navigating the New Value Paradigm
The narrative surrounding Chinese biotech assets has fundamentally shifted. According to data from the National Medical Products Administration of China, China’s innovative drug out-licensing (BD) transactions exceeded $60 billion in the first three months of 2026—already approaching half of the $135.7 billion recorded for the entire year of 2025. More telling than the volume, however, is the nature of these transactions.
A Strategic Playbook for Chinese Biotech Cross-Border Deals: Navigating the New Value Paradigm
The narrative surrounding Chinese biotech assets has fundamentally shifted. According to data from the National Medical Products Administration of China, China’s innovative drug out-licensing (BD) transactions exceeded $60 billion in the first three months of 2026—already approaching half of the $135.7 billion recorded for the entire year of 2025. More telling than the volume, however, is the nature of these transactions.
China Issues New Regulations on Countering Foreign Extraterritorial Jurisdiction: What MNCs Need to Know
On April 7, 2026, China’s State Council simultaneously promulgated two major regulations, completing a systemized countersanctions framework: the Regulations on Countering Foreign Improper Extraterritorial Jurisdiction (Decree No. 835) and the Regulations on the Security of Industrial and Supply Chains (Decree No. 834). Both took effect immediately upon publication with no grace period.
China Issues New Regulations on Countering Foreign Extraterritorial Jurisdiction: What MNCs Need to Know
On April 7, 2026, China’s State Council simultaneously promulgated two major regulations, completing a systemized countersanctions framework: the Regulations on Countering Foreign Improper Extraterritorial Jurisdiction (Decree No. 835) and the Regulations on the Security of Industrial and Supply Chains (Decree No. 834). Both took effect immediately upon publication with no grace period.
Navigating the Evolving Foreign NGO Regulatory Landscape in China
China’s rules for international NGOs are shifting, and the stakes are high. This Lawflash breaks down what is changing, what regulators now expect, and how NGOs can adjust their strategy to protect programs, partnerships, and people on the ground. In China, nonprofit and for-profit organizations are governed by distinct regulatory regimes.
Navigating the Evolving Foreign NGO Regulatory Landscape in China
China’s rules for international NGOs are shifting, and the stakes are high. This Lawflash breaks down what is changing, what regulators now expect, and how NGOs can adjust their strategy to protect programs, partnerships, and people on the ground. In China, nonprofit and for-profit organizations are governed by distinct regulatory regimes.
China Enacts First Comprehensive Regulations on Industrial and Supply Chain Security
China’s State Council on April 7, 2026 published the Regulations on Industrial and Supply Chain Security (the Regulations), which took effect immediately upon publication with no transition period. The Regulations elevate existing, disparate legal tools, such as export controls and anti-sanctions provisions, into a unified, national security–driven regulatory framework for supply chain oversight and response.
China Enacts First Comprehensive Regulations on Industrial and Supply Chain Security
China’s State Council on April 7, 2026 published the Regulations on Industrial and Supply Chain Security (the Regulations), which took effect immediately upon publication with no transition period. The Regulations elevate existing, disparate legal tools, such as export controls and anti-sanctions provisions, into a unified, national security–driven regulatory framework for supply chain oversight and response.
Navigating China’s New 2026 Implementing Regulations of the Drug Administration Law
The State Council of the PRC promulgated the Implementing Regulations of the Drug Administration Law (2026 Revisions) on January 27, 2026, set to take effect on May 15, 2026. This LawFlash provides a summary of the law and analyzes the strategic impact these shifts will have on foreign investors and multi-national pharmaceutical enterprises operating in the Chinese market. The 2026 Revisions represent a strategic move by the Chinese government to unify and elevate drug governance.
China’s New Tax Reporting Rules Are a Game Changer for Overseas Internet Platforms
China’s new reporting rules will require Chinese domestic and international internet platform enterprises to submit tax-related information to Chinese tax authorities. The Chinese government has introduced a set of new regulations requiring internet platforms to report tax-related information to Chinese tax authorities.
China’s Indirect Transfer Tax Rules and Implications for Cross-Border M&A Amid Evolving Enforcement
Circular 7 remains a cornerstone of China’s approach to taxing indirect transfers and continues to influence the structuring of cross-border M&A transactions. While Circular 7’s formal provisions have not changed, the way it is enforced has evolved markedly.
Morgan Lewis Advises AptarGroup on Strategic Investment in Sonmol
SHANGHAI, October 13, 2025: Morgan Lewis represented AptarGroup Inc. in its strategic investment in Sonmol. Aptar is a global leader in drug and consumer product dosing, dispensing, and protection technologies, and Sonmol is a Chinese digital respiratory therapeutics company.
Key Considerations for Restructuring Investment in China | JD Supra
Geopolitical tensions have increasingly impacted business operations in China, prompting multinational companies to adopt contingency strategies, including spin-offs or restructuring. These efforts present both challenges and opportunities, particularly when navigating government approvals, foreign exchange, merger control, and tax filing requirements in the People’s Republic of China (PRC). Understanding these factors is crucial for ensuring a smooth and compliant restructuring process.
Key Considerations for Restructuring Investment in China
Geopolitical tensions have increasingly impacted business operations in China, prompting multinational companies to adopt contingency strategies, including spin-offs or restructuring. These efforts present both challenges and opportunities, particularly when navigating government approvals, foreign exchange, merger control, and tax filing requirements in the People’s Republic of China (PRC). Understanding these factors is crucial for ensuring a smooth and compliant restructuring process.
Understanding China’s New Company Law: What Foreign Investors Need to Know | JD Supra
The amended Company Law of China (the New Company Law) took effect on July 1, 2024, making substantial changes to existing rules in a wide range of areas including, among others, new timeline requirements for capital contribution, streamlined corporate registration and filing procedures, enhanced corporate governance, and strengthened shareholder rights protections. The law applies to all companies and other covered business in mainland China, including foreign-invested enterprises (FIEs).
Understanding China’s New Company Law: What Foreign Investors Need to Know
UNDERSTANDING CHINA'S NEW COMPANY LAW WHAT FOREIGN INVESTORS NEED TO KNOW MARCH 2025 REPORT UNDERSTANDING CHINA'S NEW COMPANY LAW: WHAT FOREIGN INVESTORS NEED TO KNOW The amended Company Law of China (the New Company Law) took effect on July 1, 2024, making substantial changes to existing rules in a wide range of areas including, among others, new timeline requirements for capital contribution, streamlined corporate registration and filing procedures, enhanced corporate governance, and...
Understanding the NewCo Model: A Trending Approach of Chinese Pharmaceutical Companies | JD Supra
Inventive deal structures are on the rise within China’s life sciences industry, with the “NewCo” model having garnered significant interest among Chinese pharmaceutical companies in recent years. In 2024, several landmark deals were structured using this innovative model. So, what exactly is the NewCo model? What makes some Chinese pharmaceutical companies opt for NewCo as an alternative to a traditional license-out?
Understanding the NewCo Model: A Trending Approach of Chinese Pharmaceutical Companies
Inventive deal structures are on the rise within China’s life sciences industry, with the “NewCo” model having garnered significant interest among Chinese pharmaceutical companies in recent years. In 2024, several landmark deals were structured using this innovative model. So, what exactly is the NewCo model? What makes some Chinese pharmaceutical companies opt for NewCo as an alternative to a traditional license-out?
China Boosts Regulatory Framework for Local Pharmaceutical Manufacturing | JD Supra
In recent years, China has introduced significant changes to its Drug Administration Law and corresponding legislation, including the nationwide Market Authorization Holder (MAH) system. These reforms aim to boost foreign investment, streamline drug approvals and registration, and improve market access. However, challenges around cross-border manufacturing, intellectual property (IP), and regulatory compliance persist, impacting both local and international companies.
China Boosts Regulatory Framework for Local Pharmaceutical Manufacturing
In recent years, China has introduced significant changes to its Drug Administration Law and corresponding legislation, including the nationwide Market Authorization Holder (MAH) system. These reforms aim to boost foreign investment, streamline drug approvals and registration, and improve market access. However, challenges around cross-border manufacturing, intellectual property (IP), and regulatory compliance persist, impacting both local and international companies.
Hague Apostille Certification to Replace Legalization Process in China | JD Supra
Beginning November 7, 2023, the Apostille Convention of the Hague Conference on Private International Law will come into effect in mainland China. Upon effectiveness, the country will replace the current legalization process for cross-border documents with the apostille certification method under the Convention. This change comes after China acceded to the Convention in March 2023, joining 126 other contracting states to the Convention. The Convention will continue to apply in Hong Kong and Macao.
Hague Apostille Certification to Replace Legalization Process in China
Beginning November 7, 2023, the Apostille Convention of the Hague Conference on Private International Law will come into effect in mainland China. Upon effectiveness, the country will replace the current legalization process for cross-border documents with the apostille certification method under the Convention. This change comes after China acceded to the Convention in March 2023, joining 126 other contracting states to the Convention. The Convention will continue to apply in Hong Kong and Macao.
Production of Astaxanthin by Animal Cells via Introduction of an Entire Astaxanthin Biosynthetic Pathway
1. Introduction Astaxanthin (3,3′-Dihydroxy-β, β-carotene-4,4′-dione) is a high-value molecule classified as a ketocarotenoid, synthesized through a complex pathway, and commonly found as a unique red-orange pigment in many animals such as salmon, trout, flamingos, and crustaceans (shrimp, crab, krill, and crayfish) [,]. Although all animals cannot synthesize carotenoids de novo, except aphids (Aphis spp.) [,], they accumulate it from zooplankton, which consumes astaxanthin from phytoplankton [].
How China’s Detailed Human Genetic Resources Rules May Impact Multinational Life Science Companies | JD Supra
June 6, 2023 Mudan He, Sylvia Hu, Bonnie Li, Todd Liao Morgan Lewis + Follow x Following x Following - Unfollow Contact To embed, copy and paste the code into your website or blog: China’s Ministry of Science and Technology (MOST) officially announced on June 1, 2023 the release of the “Detailed Implementation Rules for the Management Regulations of Human Genetic Resources” (the Detailed HGR Rules).
How China’s Detailed Human Genetic Resources Rules May Impact Multinational Life Science Companies
China’s Ministry of Science and Technology (MOST) officially announced on June 1, 2023 the release of the “Detailed Implementation Rules for the Management Regulations of Human Genetic Resources” (the Detailed HGR Rules). These rules, set to take effect on July 1, 2023, represent a significant milestone in the regulation of human genetic resources (HGR) in China.
Effects of Z-VaD-Ala-Asp-Fluoromethyl Ketone (Z-VAD-FMK) and Acetyl-Asp-Glu-Val-Asp-Aldehyde(Ac-DEVD-CHO) on Inflammation and Mucus Secretion in Mice Exposed to Cigarette Smoke (pdf) | Paperity
International Journal of Chronic Obstructive Pulmonary Disease, Feb 2023 This is a preview of a remote PDF: https://www.dovepress.com/getfile.php?fileID=87304 Mudan He, Guoqing Zhang, Fang Shen, Xingjing Li. , International Journal of Chronic Obstructive Pulmonary Disease, 2023, pp. 69-78, Volume 18, DOI: 10.2147/COPD.S385748
Nanog safeguards early embryogenesis against global activation of maternal β-catenin activity by interfering with TCF factors
Loading metrics Open Access Peer-reviewed Research Article Mudan He, Ru Zhang, Shengbo Jiao, Fenghua Zhang, Ding Ye, Houpeng Wang, Yonghua Sun Mudan He, Ru Zhang, Shengbo Jiao, Fenghua Zhang, Ding Ye, Houpeng Wang, Yonghua Sun Published: July 23, 2020 https://doi.org/10.1371/journal.pbio.3000561 ? This is an uncorrected proof. Figures Abstract Maternal β-catenin activity is essential and critical for dorsal induction and its dorsal activation has been thoroughly studied.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Mudan
Contact Mudan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack